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There is a strong need for science-based risk assessment that
utilizes known data from diverse sources to arrive at accurate
assessments of human health risk. Such assessments will protect
the public health without mandating unreasonable regulation.
This paper utilizes 30 years of research on three ‘‘known human
carcinogens’’: formaldehyde, vinyl chloride (VC), and ethylene
oxide (EO), each of which forms DNA adducts identical to
endogenous DNA adducts in all individuals. It outlines quanti-
tative data on endogenous adducts, mutagenicity, and relation-
ships between endogenous and exogenous adducts. Formaldehyde
has the richest data set, with quantitative data on endogenous and
exogenous DNA adducts from the same samples. The review
elaborates on how such data can be used to inform the current risk
assessment on formaldehyde, including both the biological
plausibility and accuracy of projected risks. Finally, it extends
the thought process to VC, EO, and additional areas of potential
research, pointing out needs, nuances, and potential paths
forward to improved understanding that will lead to strong
science-based risk assessment.
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DNA adducts represent key events in mutagenesis and
carcinogenesis. For many years, they were thought to be solely
the product of exposure to chemical carcinogens. In the past 25
years, however, select DNA adducts were also identified in
cellular DNA from tissues of animals and humans not known to
be exposed to carcinogens. A major pathway for the formation
of such endogenous DNA adducts has been shown to be
oxidative stress (Ames, 1989; Dedon, 2008; Dedon et al., 1998;
Lunec, 1998; Marnett, 2000; Swenberg et al., 2008). However,
oxidative stress is not the only cause of endogenous DNA
damage, as formaldehyde and acetaldehyde also induce DNA
adducts. The most common endogenous lesions found in DNA
are the aldehydic lesions associated with apurinic/apyrimidinic
sites that arise from the loss of DNA bases because of oxidative
stress and chemical depurination of alkylated and normal bases
(Lindahl, 1993; Lindahl and Andersson, 1972; Nakamura et al.,
1998, 2000; Nakamura and Swenberg, 1999). Many of the
endogenous DNA lesions can result in mutations if DNA
replication takes place before they are repaired. Considerable
evidence is now accumulating on the numbers of endogenous
DNA adducts that are normally present in human and animal
cells. Highly sensitive assays are providing accurate data on the
quantity of many endogenous adducts. In our laboratory, we
utilize Liquid Chromatography-tandem Mass Spectrometry
(LC-MS/MS) and slot blot analyses, taking great care to avoid
artifacts. Table 1 illustrates the top 10 endogenous lesions that
are measured routinely in our laboratory. These data are
presented as ‘‘DNA lesions per cell’’ in order to emphasize the
point that even without exogenous exposure to carcinogens, our
DNA is far from pristine. This collection of data is most
certainly an underestimate of the total number of endogenous
DNA lesions, as there are many adducts that we have not
examined. It is very likely that every cell has a steady-state
background of at least 50,000 endogenous DNA lesions. Under
conditions of oxidative stress, this number is expected to
increase. In addition to this expanded knowledge on endoge-
nous DNA adducts, the field has greatly benefited from
advances in analytical instrumentation (Singh and Farmer,
2006). Just in the last decade, LC-MS/MS instruments have
increased detection limits by 10- to 1000-fold. These increases
were brought about by the combination of improvements from
several technologies, including mass spectrometry (MS) in-
strumentation with improved ion transmission and detection
capabilities, the introduction of ultraperformance liquid chro-
matography (UPLC) (Churchwell et al., 2005), and the use of
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capillary-LC, nano-LC, and chip systems allowing for lower
mobile-phase flow rates and improved electrospray ionization
efficiency (Koster and Verpoorte, 2007; Sikanen et al., 2010).
Finally, as stressed in this paper, the use of stable isotope
exposures has permitted new approaches that allow distinguish-
ing endogenous and exogenous DNA adducts.
With such florid amounts of DNA damage always present,
we expect this background damage to result in ‘‘spontaneous’’
mutations and to be causally involved in the induction of
cancer (Ames, 1989; Swenberg et al., 2008). Whereas
exogenous DNA adducts are expected to have a dose-response
that declines linearly toward zero when exposures are below
those that saturate the metabolic activation of procarcinogens,
deplete detoxication, or saturate DNA repair pathways. In
contrast, mutations always have a quantifiable nonzero
background level. There are critical differences between
‘‘biomarkers of exposure,’’ i.e., DNA adducts, that are
repairable and ‘‘biomarkers of effect,’’ i.e., mutations, that
are heritable. We and others have proposed that these
background mutations represent the biology expected to arise
from endogenous DNA damage (Jarabek et al., 2009; Loeb and
Harris, 2008; Swenberg et al., 2008). This has important
implications for epidemiology and quantitative risk assessment.
Cancer is a disease of mutations, so an understanding of
mutagenic responses at low exposures represents critical
information for establishing causality and estimating cancer
risk.
In 2005, Dr Chris Wild brought forward the concept of the
‘‘exposome,’’ highlighting the importance of greater under-
standing of human exposure and emphasizing the need to not
only focus on traditional ‘‘Omics’’ in the pursuit of disease
reduction (Wild, 2005). This concept has since been expanded
in an editorial by Smith and Rappaport (2009) and a meeting at
the National Academy of Science held in 2010 (NAS, 2010).
The exposome encompasses life course environmental expo-
sures, including lifestyle factors, from the prenatal period
onward. It represents a comprehensive measurement of all
exposure events, both exogenous and endogenous, from
conception to death. This includes electrophilic molecules that
are generated in living cells and organs through normal
physiology, lifestyle, and nutrition. The role of endogenous
electrophiles in causing Biomarkers of Exposure and Effect in
disease causation, as previously reviewed (Jarabek et al., 2009;
Swenberg et al., 2008), is consistent with this concept.
Although epidemiology has clearly made many seminal
discoveries related to causes of human cancer, there has been
a recent call for ‘‘epistemological modesty’’ in the field to
reduce the likelihood of false-positive results (Boffetta et al.,
2008). Likewise, the recent publication of Science and
Decisions (NRC, 2009) suggests that understanding and using
Mode of Action in science-based risk assessment is too
complicated and concluded that one should simplify cancer and
noncancer risk assessments by only considering linear assess-
ments of risk. As the Society of Toxicology celebrates its 50th
anniversary, simplifying or ignoring the science, rather than
embracing its complexity, fails to make use of our increasing
knowledge of biology, genetics, genomics, and metabolomics,
and it certainly does not embrace the plea to consider the
exposome.
This paper focuses on three chemicals that the International
Agency for Research on Cancer (IARC) has classified as
‘‘known human carcinogens’’: formaldehyde, vinyl chloride
(VC), and ethylene oxide (EO). All three induce exogenous
DNA adducts that are identical chemically to endogenously
formed DNA adducts. Thus, DNA adducts that have the same
structure and mutational efficiency as those formed from
exposure to these three chemicals are always present in DNA,
even when there has been no environmental or occupational
exposure. MS analysis allows the use of stable isotope exposures
or radioisotope exposures combined with chromatographic
separation and accelerator MS (AMS) to compare and contrast
the number of identical endogenous and exogenous adducts
present under various exposure scenarios. Thus, it is now
possible to determine how much of the molecular dose that is
present in DNA came from the exogenous exposure and how
much was induced by normal biochemistry in the absence of
environmental or occupational exposure. Gaining a better
appreciation for these relationships will clearly lead to
strengthened evidence for or against causality and more effective
use of scientific information in chemical-specific quantitative
risk assessments. In both epidemiology and risk assessment,
enhanced understanding of endogenous and exogenous DNA
adducts can be used to place bounds on the plausibility and
potency of exogenous exposures to induce disease.
This paper presents an overview of evidence for the
existence of specific endogenous DNA adducts of formalde-
hyde, VC, and EO, followed by sections on sources of
endogenous DNA adducts, amounts of DNA adducts, and
a short discussion of the mutagenic properties of various DNA
adducts when available. This is followed by recent compar-
isons of endogenous and exogenous DNA adduct numbers
associated with exposure to labeled formaldehyde, VC, or EO.
TABLE 1
Steady-State Amounts of Selected endogenous DNA Damage
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Data are now available for all three of the known human
carcinogens in laboratory animals and humans, so comparisons
of exogenous and endogenous adducts can be made with
reasonable accuracy. Data on formaldehyde are clearly the
most robust. We summarize recent findings and then examine
its application to proposed risks using new methods to
determine how molecular dosimetry information on exogenous
and endogenous DNA adducts can influence low-dose risk
estimates. We then discuss these issues in relation to the
biological plausibility of cancer causation and the low-dose
linear risk assumption. Similar approaches are briefly discussed
for VC and EO, as those databases are less robust. Finally, we
address gaps in our knowledge, potential future research, and
implications of this approach for current issues.
FORMALDEHYDE
Formaldehyde is classified as a known human and animal
carcinogen according to the IARC (IARC, 2006), causing
nasopharyngeal cancer (NPC) in humans and squamous cell
carcinomas in the nasal passages of rats (Kerns et al., 1983;
Monticello et al., 1996; Swenberg et al., 1980). Additionally,
limited epidemiological evidence for the induction of leukemia
(LEU) in humans is available (Beane Freeman et al., 2009;
Coggon et al., 2003; Hauptmann et al., 2003, 2004, 2009;
Marsh et al., 2010). However, whether or not formaldehyde
causes LEU remains debatable, as experimental data do not
support the induction of LEU (Lu et al., 2010a). As a high-
volume industrial chemical, formaldehyde can enter the body
through a variety of environmental exposures. Of equal
importance, formaldehyde is also an essential metabolic in-
termediate generated endogenously from serine, glycine,
methionine, and choline and also produced from metabolism
of xenobiotic chemicals and proteins by demethylation.
Formaldehyde-DNA Adducts and Mutagenicity
Formaldehyde is a very reactive compound, directly
targeting diverse nucleophiles of DNA and protein. Typically,
formaldehyde can induce DNA adducts including N2-
hydroxymethyl-deoxyguanosine (dG), N6-hydroxymethyl-
deoxyadenosine (dA), and N4-hydroxymethyl-deoxycytosine
(dC) in vitro. Those DNA adducts are considered to be
promutagenic, as the adduction occurs on the amino groups
participating in Watson-Crick base pairing. Numerous experi-
ments have demonstrated that formaldehyde exposure induces
mutations in a variety of test systems ranging from bacteria to
laboratory animals. In Escherichia coli, exposure to 4 mmol/l
formaldehyde for 1 h induced large insertions (41%), large
deletions (18%), and point mutations (41%) in the xanthine
guanine phosphoribosyl transferase gene (Crosby et al., 1988).
The point mutations were transversions at GC base pairs, as
revealed by DNA sequencing. GC / TA transversions were
also found in E. coli Lacþ WP3104P and in S. typhimurium
Hisþ TA7005 after formaldehyde exposure (Ohta et al., 1999,
2000). DNA sequencing demonstrated that AT / CG
transitions were the predominant point mutations in formalde-
hyde-induced human lymphoblast TK6 X-linked hypoxanthine
guanine phosphoribosyl-transferase (HPRT) mutants (Liber
et al., 1989). Formaldehyde exposure did not induce gene
mutations in the HPRT locus in Chinese hamster V79 cells, but
other genotoxic effects such as DNA-protein cross-links, sister
chromatid exchange, and micronuclei were found (Merk and
Speit, 1998). In addition, several point mutations have been
identified by DNA sequence analysis of p53 complementary
DNA from formaldehyde-induced squamous cell carcinomas in
nasal tissues of rats, including 396C / A (codon 132), 398G /
T (codon 133), 638G / T (codon 213), 812G / A (codon 271),
and 842G / C (codon 281) (Recio et al., 1992).
Endogenous Formaldehyde-DNA Adducts
As mentioned above, formaldehyde is an essential metabolic
intermediate generated in all living cells. The endogenous
formaldehyde concentration in human blood is ~100lM, which
induces endogenous formaldehyde-DNA adducts. The number
of endogenous N2-hydroxymethyl-dG adducts in rats was
measured by LC-MS/MS and found to be ~1–7 adducts/107
dG (Lu et al., 2010a). The number of endogenous N6-
hydroxymethyl-dA adducts in rats was also quantified and
shown to be ~1–3 adducts/107 dA across a range of tissues
(Cheng et al., 2008; Lu et al., 2010a). The formation of
formaldehyde-DNA adducts in humans has also been demon-
strated. The adduct number of endogenous N6-hydroxymethyl-
dA was determined as ~0.7 adducts/107 adducts in human
leukocytes (Wang et al., 2009). We now have additional data on
endogenous N2-hydroxymethyl-dG adducts in primates where
higher numbers of endogenous adducts have been measured in
bone marrow (Moeller et al., 2011).
Relationships of Exogenous/Endogenous Formaldehyde-
DNA Adducts
Quantifying the number of adducts caused by exposure to
formaldehyde has proven difficult because it is confounded by
the presence of a substantial natural background of formalde-
hyde adducts. Recently, our laboratory has employed [13CD2]-
formaldehyde for exposure, coupled with highly sensitive MS
analyses (Lu et al., 2010a; Lu et al., 2010b; Moeller et al.,
2011). This unique strategy allowed us to distinguish DNA
adducts originating from endogenous and exogenous sources
of formaldehyde based on the different transitions used in
selected reaction monitoring (SRM) mode (Fig. 1). The
exogenous DNA adducts have a 3 Da mass increase because
of the use of [13CD2]-formaldehyde. Through this approach,
we have been able to accurately quantify both endogenous and
exogenous adducts induced by formaldehyde. The first
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molecular dosimetry study was carried out by exposing rats to
10 pmm [13CD2]-formaldehyde for 1 day (6 h/day) or 5 days
(6 h/day) (Lu et al., 2010a). The number of exogenous N2-
HO13CD2-dG in 1-day and 5-day nasal DNA samples from rats
exposed by inhalation to 10 ppm [13CD2]-formaldehyde was
1.28 ± 0.49 and 2.43 ± 0.78 adducts/107 dG, respectively. The
number of endogenous N2-HOCH2-dG adducts was 2.63 ±
0.73 and 2.84 ± 1.13 adducts/107 dG. In addition, 3.95 ±
0.26 and 3.61 ± 0.95 N6-HOCH2-dA endogenous adducts/
107 dA were present, but no exogenous dA adducts were
detected. The ratios of exogenous versus endogenous dG adducts
were 0.57 ± 0.28 and 1.06 ± 0.40 for the 1-day– and 5-day–
exposed groups, respectively. This study also examined sites
distant from the point of contact but did not detect exogenous
adducts in any distant tissues, such as bone marrow, spleen,
thymus, and white blood cells, whereas endogenous dG and dA
adducts were present in all tissues analyzed. In order to increase
the likelihood of measuring [13CD2]-labeled exogenous adducts in
sites distant to the point of contact, approximately five times more
DNA was analyzed.
More recently, we have expanded our studies on molecular
dosimetry of formaldehyde-DNA adducts by exposing rats to
0.7, 2, 5.8, 9.1, and 15.2 ppm [13CD2]-formaldehdye for 1 day
(6 h/day), which modeled the exposures in a previous cell
proliferation and carcinogenicity study (Monticello et al.,
1996). Formaldehyde induced nasal squamous cell carcinomas
in a highly nonlinear fashion, with no nasal carcinomas at 0.7
and 2 ppm but 1, 22, and 47% carcinomas at 6, 10, and 15 ppm
formaldehyde. The exogenous dG adducts were 0.039 ± 0.019,
0.19 ± 0.08, 1.04 ± 0.24, 2.02 ± 0.43, and 11.15 ± 3.01 for 0.7,
2, 5.8, 9.1, and 15.2 ppm exposure, respectively, which clearly
illustrated a nonlinear exposure-response, as demonstrated by
the fact that 21-fold exposure increase (0.7–15.2 ppm) induced
287-fold higher amounts of exogenous DNA adducts in rat
nasal epithelium (Fig. 2). In addition, the ratios of exogenous
versus endogenous were determined to be 0.011 ± 0.001,
0.033 ± 0.006, 0.19 ± 0.04, 0.66 ± 0.17, and 2.78 ± 1.08,
respectively, for the [13CD2]-formaldehdye exposures, clearly
demonstrating that endogenous DNA adducts predominate at
low-dose exposures.
Moreover, we have carried out a primate study that
exposed monkeys to 1.9 or 6.1 ppm isotope-labeled
formaldehyde for 2 days (6 h/day). The exogenous dG
adducts in nasal DNA of monkeys after the 2-day exposures
were similar to that of rats exposed to 2 ppm for 1 day,
whereas the exogenous dG adducts were ~2.5-fold lower in
monkeys exposed to 6.1 ppm [13CD2]-formaldehdye for
2 days (6 h/day) compared with rats exposed to 5.8 ppm for
1 day (Fig. 3). These data demonstrated that lower numbers
of exogenous DNA adducts were formed in nasal turbinates
of nonhuman primates than rats after inhalation exposure to
formaldehyde. Moreover, our preliminary data indicate that
primates have two- to threefold higher endogenous dG
FIG. 1. Formation of hydroxymethyl DNA adducts induced by formaldehyde.
FIG. 2. Molecular dosimetry of N2-hydroxymethyl-dG adducts in rats
exposed to formaldehyde.
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adducts in tissues we analyzed. This substantially higher
background of endogenous adducts further reduces the ratio
of exogenous/endogenous formaldehyde adducts in primates
exposed to low concentrations.
Furthermore, we performed a study to determine the half-life
of exogenous formaldehyde-DNA adducts. Rats were exposed
to 10 ppm [13CD2]-formaldehyde for 1 day (6h) and then
sacrificed at 0, 6, 12, 24, 48, or 72 h, respectively. The data
showed a rapid loss of nearly half of the adducts during the first
6 h postexposure, followed by a constant rate of loss over the
rest of the 72-h experiment (Lu, unpublished data). The initial
decrease in [13CD2] adducts is thought to result from cell death
because of cytotoxicity, followed by a half-life of ~94 h. When
10-ppm exposures occur daily, this scenario repeats itself. That
explains why 5 days of exposure only doubled the number of
exogenous adducts.
Application of Data on Endogenous/Exogenous Adducts to
Formaldehyde Risk
On 2 June 2010, the U.S. Environmental Protection Agency
(U.S. EPA) released its draft Toxicological Review of Form-
aldehyde—Inhalation Assessment, which reviews the extraordi-
narily rich database that exists for formaldehyde toxicity and
carcinogenicity and describes inferences regarding potential
human health risks from environmental formaldehyde expo-
sures that the Agency has drawn from its consideration of this
database (U.S. EPA, 2010). In particular, this document sets
out a ‘‘preferred (plausible upper bound) unit risk estimate’’ of
0.081 per ppm that is based on adult human data for NPC,
Hodgkin lymphoma (HL), and LEU. After application of age-
dependent adjustment factors (ADAFs), the overall (plausible
upper bound) unit risk estimate that the Agency considers
applicable to ‘‘full lifetime’’ formaldehyde exposures is
increased further to 0.13 per ppm. In other words, the Agency
is suggesting that as many as 13% of people (approximately
one in eight) who are exposed continuously to 1 ppm
formaldehyde could develop one or more of these three
cancers. The U.S. EPA document also presents the individual
unit risk estimates for each of these cancers (0.011/ppm for
NPC, 0.017/ppm for HL, and 0.057/ppm for LEU) that were
derived by the Agency using (adult) epidemiologic data and
cumulative formaldehyde exposure as the dose metric (see
Table 6-3, pp 6–41, 6–42 of the draft).
Are these high estimates of extra lifetime human cancer risk
credible, even as ‘‘plausible’’ upper bounds? Do they arise as
a consequence of real causal associations between workers’
cancer risks and their actual formaldehyde exposures as has
been asserted by the Agency? Or, are there other plausible
explanations such as small numbers of cancer deaths, residual
bias, and uncertainty in the characterization of occupational
exposures to formaldehyde and/or other risk factors? We can
begin to develop answers to these questions by taking
advantage of the newly acquired information regarding specific
DNA adducts that arise from the chemical interaction of DNA
with formaldehyde of either endogenous or exogenous (in-
haled) origin (Lu et al., 2010a; Lu et al., 2010b; Moeller et al.,
2011). As has already been noted, these adducts constitute
a highly sensitive and specific biomarker of exposure (dose
metric) and potential effects (mutations and subsequent cancer
development) that is far superior to the necessarily coarse
exposure characterizations that have been developed as part of
retrospective cohort mortality investigations.
Recent studies employing stable isotope-labeled formalde-
hyde afford the ability to differentiate between formaldehyde
molecules of endogenous and exogenous origin (Lu et al.
2010a; Lu et al., 2010b; Moeller et al., 2011). Such research
also makes it possible to develop cancer risk estimates with
a unique ‘‘bottom-up’’ approach that extrapolates upward from
background (endogenous) exposure and response, as opposed
to the typical ‘‘top-down’’ approach that often requires
downward extrapolation from exogenous exposure levels so
extreme as to be potentially irrelevant to the potential risks that
might be present at the far lower environmental exposures that
are of primary interest. We propose herein a simple empirical
model of human cancer risk for conservatively bounding the
extra lifetime cancer risk that might arise from low-level
formaldehyde exposures, relying upon the dG adduct data as
the dose metric and a conservative linear dose-response model.
Extra risk estimates obtained with this bottom-up approach can
then be compared with those put forward by U.S. EPA in its
draft assessment document.
The data of Lu et al. (Lu et al. 2010a; Lu et al., 2010b;
Moeller et al., 2011) for dG monoadducts have been
summarized in Table 2. In what follows, we have utilized the
dG adduct data for each combination of concentration, number
of 6-h exposures, species, and tissue to develop the alternative
human cancer risk estimates that are presented in Table 3. The
sample size for each dG adduct determination was first used to
convert SDs into corresponding SEs as shown in Table 3. The
SEs were then used to compute lower 95% confidence bounds
FIG. 3. Formation of exogenous dG adducts in rats and monkeys exposed
to 1.9 and 6.1 ppm formaldehyde (1-day exposure for rats and 2-day exposure
for monkeys).
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on the numbers of ‘‘endogenous’’ dG adducts in nose, bone
marrow, and blood (white blood cells).
Because no exogenous dG adducts were detected in any of
the distant site tissues, including bone marrow and mono-
nuclear white blood cells, we can state with confidence that if
such exogenous adducts were present in these tissues, then
their amounts would necessarily have been smaller than the
LC-MS/MS-SRM method’s limit of detection (LOD). We have
therefore used the method’s LOD (reported as 240 3 1018
mol, Lu et al., 2010a or 20 3 1018 mol, Lu et al., 2010b) as
a worst-case upper bound on the level of exogenous dG
adducts that could be present in bone marrow or mononuclear
white blood cells. The above molar LODs were converted to
the equivalent 0.0177 or 0.000946 adducts per 107 dG,
respectively, using the amount of rat or monkey DNA collected
in the distant site tissue samples and the amount of guanine
(0.22 for rats and 0.20 for monkeys, expressed as a fraction)
that is present in DNA (Casanova et al., 1989, 1991).
Because the endogenous and exogenous dG adducts are
chemically indistinguishable following an environmental
exposure, we assume that both are implicated to the same
extent in the carcinogenicity of low exposures to formalde-
hyde. The dose-response model that we propose is very simple:
a direct, proportional (i.e., linear) relationship between cancer
incidence and dG adducts, at least up until local formaldehyde
tissue concentrations become so high as to cause cytotoxicity
and related increases in cell proliferation. At exposures of 6
ppm and higher, one would expect to see greater than linear,
i.e., nonlinear increases in cancer risk with increasing
formaldehyde exposure, and our linear model would need to
be elaborated with a multiplicative cell proliferation component
to reflect appropriately these high dose–only phenomena.
Our risk model implies that both endogenous and exogenous
dG adducts give rise to proportional tissue-specific risks
of cancer development. If p0 represents the background
risk of tissue-specific cancer attributable to endogenous
formaldehyde-dG adducts and c0(dG) represents the tissue-
specific level of such adducts, then the ratio, a0 ¼ p0/c0(dG),
provides an estimate of the unit risk, or potency, of
formaldehyde-dG adducts to cause tissue-specific cancer, i.e.,
it represents the incremental cancer risk attributable to a single
adduct per 107 dG.
We do not know the true value of p0 because we do not
know the complete mechanism of cancer development in
relation to the formation of formaldehyde-dG adducts in
tissues, but we do know that p0 cannot be any greater than the
total background risk of developing a specific cancer (p0); so in
generating our human estimates of cancer risk, we have
assumed that all of the total background risks of specific
cancers such as NPC, HL, or LEU, are attributable to the level
of endogenous formaldehyde-dG adducts in the associated
tissues, namely, nose, bone marrow, or mononuclear white
blood cells. For NPC, we used the lifetime probability provided
in the U.S. EPA draft document, namely, 7.25 3 104 (Table
C-1, pp. C-3 and Section 5.2.2). For HL (2.3 3 103) and LEU
(1.3 3 102), we used the both sexes, all race lifetime risk
estimates that are provided in Table 1.14 of SEER Cancer
Statistics Review 1975–2007 (Altekruse et al., 2010).
We have also assumed that steady-state exogenous dG
adduct levels achieved with a continuous 24 h/day, 7 days/
week exposure regimen are related to the amounts measured
at each time point in the various adduct experiments as
would be predicted by a simple one-compartment kinetic
model having a 94-h elimination half-life for exogenous dG
adducts (Lu, unpublished data) (mean lifetime ¼ 94/ln(2) ¼
135.6 h). For example, if A6 represents exogenous dG
adducts measured following a single 6-h exposure to a given
airborne formaldehyde concentration, As-s represents the
asymptotic steady-state resulting from continuous exposure
to the same concentration, and T represents the mean adduct
lifetime, then As-s ¼ A6/[1  exp(-6/T)] ¼ A6 3 23.11. Sim-
ilarly, if A30 represents exogenous dG adducts measured fol-
lowing two 6-h exposures on consecutive days, then As-s ¼
A30/{[1  exp(-6/T)] 3 [1 þ exp(-24/T)]} ¼ A30 3 12.57.
Finally, if A102 represents exogenous dG adducts measured
following five 6-h exposures on consecutive days, then As-s ¼
A102/{[1  exp(-6/T)] 3 [1 þ exp(-24/T)] þ exp[-48/T] þ
exp[-72/T] þ exp[-96/T]} ¼ A102 3 6.38.
To extrapolate from risks estimated at each measured adduct
level to those expected at other airborne formaldehyde
TABLE 2
Formaldehyde-Induced N2-Hydroxymethyl-dG Adducts in Rats
Exposed to 10 ppm Formaldehyde for 1 Day or 5 Days, Rats
Exposed to Different Concentrations of Formaldehyde for 1







(adducts/107 dG ± S.D.)
Endogenous Exogenous
Rat 10 ppm/1 day Nose 2.63 ± 0.73 1.28 ± 0.49
Bone marrow 1.05 ± 0.14 n.d.
Blood 1.28 ± 0.38 n.d.
10 ppm/5 day Nose 2.84 ± 1.13 2.43 ± 0.78
Bone marrow 1.17 ± 0.35 n.d.
Blood 1.10 ± 0.28 n.d.
Rat 0.7 ppm/1 day Nose 3.62 ± 1.33 0.039 ± 0.011
2 ppm/1 day Nose 6.09 ± 3.03 0.19 ± 0.08
5.8 ppm/1 day Nose 5.51 ± 1.06 1.04 ± 0.24
9.1 ppm/1 day Nose 3.41 ± 0.46 2.03 ± 0.43
15.2 ppm/1 day Nose 4.24 ± 0.92 11.15 ± 3.01
Bone marrow 18.2 ± 0.47 n.d.
Monkey 2 ppm/2 days Nose 2.49 ± 0.40 0.25 ± 0.04
Bone marrow 17.5 ± 2.6 n.d.
6 ppm/2 days Nose 2.05 ± 0.54 0.41 ± 0.05
Bone marrow 12.4 ± 3.6 n.d.
Note. n.d., not detected.
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concentrations, we have assumed that the relationship
between airborne formaldehyde concentration and exogenous
dG adducts is linear through zero. Given the nonlinear
relationship between dG adducts and airborne concentration
that was demonstrated in the dosimetry study of Lu et al.
(2010b), this assumption will tend to overestimate
exogenous adducts at lower concentrations, leading to
overestimation of the associated cancer risks.
Finally, we assume that the levels of endogenous and
exogenous dG adducts found in various rat and primate tissues
are representative of those that would be found in correspond-
ing human tissues after adjusting for species differences in the
average flux of inhaled formaldehyde onto surfaces of the
respiratory tract. Preliminary results have demonstrated that
similar numbers of adducts are formed in rats following
a single 6-h exposure and in monkeys exposed to 1.9 ppm for
2 days, thus monkeys get approximately half of the molecular
dose that a rat receives. We have used the same rat/human
respiratory tract flux ratio (0.46) that U.S. EPA employed in its
multistage Weibull time-to-tumor analysis of rat nasal tumors
from the Chemical Industry Institute of Toxicology inhalation
bioassays (Section 5.3.6.2 and Table 5-24 in the draft
document, U.S. EPA, 2010). For risk estimates derived from
the monkey adduct data, we have assumed that the correspond-
ing monkey/human respiratory tract flux ratio is equal to 1.
Table 3 presents the results from using the bottom-up linear
extrapolation model and the above-noted assumptions and dG
adduct data to calculate upper bound estimates of extra lifetime
cancer risk from continuous exposure to 1 ppm formaldehyde.
For NPC, our upper bound extra risk estimates span a near
20-fold range from a low of 0.39 3 103 (using monkey data
for two 6-h exposures to 6.1 ppm) up to 7.49 3 103 (using rat
data for one 6-h exposure to 15.2 ppm). Despite this broad
range, all our NPC risk estimates are smaller than the
corresponding U.S. EPA estimate of 1.1 3 102.
Our estimates of HL and LEU risk diverge even more
dramatically from the corresponding U.S. EPA estimates. At
1 ppm, our two HL estimates are less than a factor of 3.1
TABLE 3
Comparison of Extra Lifetime Risks of Developing NPC, HL, and LEU from Continuous Exposure to 1 ppm Formaldehyde as
Estimated Herein Using Formaldehyde-dG Adduct Data (dG-A) from Lu et al. (2010a), Lu et al. (2010b) and Moeller et al. (2011),






















NPC 7.25 3 104 2.84 ± 0.51a 3.61 3 104 2.43 ± 0.29 1.22 3 103a 1.1 3 102 9.03
2.63 ± 0.30b 3.39 3 104 1.28 ± 0.17 2.18 3 103b 5.05
4.24 ± 0.41c 2.03 3 104 11.15 ± 1.35 7.49 3 103c 1.47
3.41 ± 0.21d 2.36 3 104 2.03 ± 0.19 2.65 3 103d 4.16
5.51 ± 0.53e 1.56 3 104 1.04 ± 0.12 1.41 3 103e 7.81
6.09 ± 1.52f 2.02 3 104 0.19 ± 0.040 0.96 3 103f 11.4
3.62 ± 0.77g 3.08 3 104 0.039 ± 0.011 0.86 3 103g 12.8
2.05 ± 0.27h 4.50 3 104 0.41 ± 0.025 0.39 3 103h 28.5
2.49 ± 0.23i 3.42 3 104 0.25 ± 0.020 0.54 3 103i 20.5
HL 2.3 3 103 1.10 ± 0.16a 2.76 3 103 < 1.77 3 102j < 6.78 3 105j 1.7 3 103 > 251
1.29 ± 0.19b 2.36 3 103 < 1.77 3 102j < 20.9 3 105j > 81.2
LEU 1.3 3 102 1.17 ± 0.20a 1.55 3 102 < 1.77 3 102j < 3.81 3 104j 5.7 3 102 > 149.4
1.05 ± 0.081b 1.42 3 102 < 1.77 3 102j < 12.6 3 104j > 45.2
12.4 ± 1.82h 1.38 3 103 < 1.03 3 103k < 2.96 3 106k > 19,256
17.5 ± 1.31i 0.85 3 103 < 1.03 3 103k < 5.47 3 106k > 10,420
Note. UCL, Upper Confidence Limit
aAdduct data for rats after five 6 h exposure to 10 ppm (from Lu et al., 2010a).
bAdduct data for rats after one 6-h exposure to 10 ppm (from Lu et al., 2010a).
cAdduct data for rats after one 6-h exposure to 15.2 ppm (from Lu et al., 2010b).
dAdduct data for rats after one 6-h exposure to 9.1 ppm (from Lu et al., 2010b).
eAdduct data for rats after one 6-h exposure to 5.8 ppm (from Lu et al., 2010b).
fAdduct data for rats after one 6-h exposure to 2.0 ppm (from Lu et al., 2010b).
gAdduct data for rats after one 6-h exposure to 0.7 ppm (from Lu et al., 2010b).
hAdduct data for monkeys after two 6-h exposure to 6 ppm (from Moeller et al., 2011).
iAdduct data for monkeys after two 6-h exposure to 2 ppm (from Moeller et al., 2011).
jExogenous dG adducts were not detected in the blood or bone marrow. Upper bound extra risk estimates are based on the LOD in Lu et al. (2010a), namely,
0.0177 adducts per 107 dG.
kExogenous dG adducts were not detected in the bone marrow of monkeys exposed to 6 or 2 ppm. Upper bound extra risk estimates for these cases are based on
the average LOD in Moeller et al. (2011), namely, 0.001034 adducts per 107 dG.
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apart from each other but are 81-fold and more than 250-
fold, respectively, lower than U.S. EPA’s estimate of 1.7 3
103. Our LEU estimates range from 45-fold (using rat data
for one 6-h exposure to 10 ppm) to more than 19,000-fold
(using monkey data for two 6-h exposures to 6.1 ppm) lower
than the U.S. EPA estimate of 0.057. At 1 ppb, our lifetime risk
estimates for these two cancers are thus all well below the
de minimus 1 3 106 level. The marked disparities between
the adduct-based and epidemiology-based cancer risk estimates
for distant sites suggest strongly that the excess risks of HL and
NPC that have been reported in association with occupational
formaldehyde exposures cannot be due to formaldehyde. If our
plausible assumption that formaldehyde-dG adducts provide
a valid molecular dosimeter for relating potential human cancer
risks to formaldehyde exposure, the far larger risks derived
from adult human data are simply not credible.
We are confident that the risk estimates obtained from this
simple risk assessment model are conservative for several
reasons. Most importantly, this model attributes all the
background risk of specific cancers to the endogenous
formaldehyde-dG adducts that are found in the corresponding
tissues. This background risk automatically includes any
contributions to lifetime risk that come from childhood years,
so ADAFs do not need to be applied to our risk estimates.
Second, we only included the endogenous dG adducts in our
risk calculations, even though there are even higher endoge-
nous dA adducts present in the tissues (inclusion of other
adducts would further reduce the slope of the assumed linear
dose-response relationship between cancer risk and adduct
levels). Third, the risk model is linear (and conservative) at low
doses because it is, in fact, linear at all doses. Fourth, we used
lower 95% confidence bounds on measured endogenous adduct
levels to generate corresponding upper 95% confidence bounds
on the slope of the model-implied linear relationship between
cancer risks and dG adduct levels. Fifth, we have made
conservative assumptions on kinetics and dG adduct half-life
data in converting adducts measured after a 6 h/day, 5 days/
week exposure regimen to those that would be expected from
lifetime continuous 24 h/day exposures and in scaling up the
respiratory tract deposition of formaldehyde from rats to
humans using the same methods that were utilized by the U.S.
EPA.
Opportunities exist to replace assumptions that we have
made in the absence of information, with data-driven
alternatives. For example, our preliminary primate data
(Table 2 and Fig. 3) will be expanded to include the
distribution of dG adducts in five locations of the nasal
passages, trachea, bronchi, and proximal and distal lung, as
well as many additional tissues. This will shed light on
potential species differences and the effects of oral/nasal
breathing versus obligatory nasal breathing in rats in the
formation of such adducts. In addition, it should be
reasonably easy to obtain data for endogenous formaldehyde
adducts in human tissues. We have submitted an Institutional
Review Board protocol to evaluate this. Such data could be
used to confirm and/or replace the plausible dosimetric
assumption that endogenous formaldehyde-dG adduct levels
are similar in rats, monkeys, and humans.
The methodology of Lu et al. (Lu et al. 2010a; Lu et al.,
2010b; Moeller et al., 2011) differentiates clearly between
formaldehyde molecules of endogenous and exogenous (in-
haled) origin. This remarkable achievement makes it possible
to develop cancer risk estimates with a unique bottom-up
approach that extrapolates upward from background (endog-
enous) exposures and responses, as opposed to the typical top-
down extrapolation from cancer incidence in laboratory
animals subjected to extremely high exposure concentrations.
The simple linear exposure-response model we have used to
estimate upper bound lifetime human NPC, HL, and LEU risks
from inhaled formaldehyde at exposure concentrations of
1 ppm and below capitalizes on this new molecular dosimetry
information. Comparison of our risk estimates with corre-
sponding estimates from the U.S. EPA draft document shows
the latter to be markedly higher. This discrepancy between
results obtained with molecular dosimetry and those that rely
on highly uncertain retrospective exposure reconstructions calls
into serious question the credibility of attributing increased
human mortality from these cancers, particularly at distant
sites, to occupational formaldehyde exposures.
For example, endogenous and N2-[13CD2]-hydroxymethyl-
dG adducts were readily measured in 20–30 lg of nasal
DNA from nonhuman primates; however, no N2-[13CD2]-
hydroxymethyl-dG adducts were detectable when 312 lg of
bone marrow DNA was analyzed. In contrast, high numbers of
endogenous N2-hydroxymethyl-dG adducts were present in
bone marrow DNA. The number of endogenous adducts in the
312-lg sample of bone marrow DNA was 13.9 adducts/107
dG. If one constructs a worst-case scenario by assuming that
exogenous adducts were just below the LOD in this sample,
less than 1 N2-[13CD2]-hydroxymethyl-dG adduct/10
10 dG
could have existed. This would mean that less than one
exogenous DNA adduct was present for every 13,900
endogenous formaldehyde adducts. It is difficult to conceive
of a mechanism by which 1/13,900 identical DNA adducts
could drive the biology that leads to carcinogenesis.
In summary, the use of stable isotope formaldehyde
exposures has provided new insight and tools for science-
based risk assessment. The fact that formaldehyde is present in
every living cell cannot be ignored when conducting a cancer
risk assessment for inhaled formaldehyde. Until now, we have
not known what the relationship was between the number
of exogenous DNA adducts derived from the inhaled
formaldehyde exposure and the number of endogenous
adducts present in bone marrow. Now that the relationship
is known, we have to seriously question the biological
plausibility that inhaled formaldehyde causes LEU and HL,
and start asking much more probing questions about the
epidemiology data.
ENDOGENOUS VERSUS EXOGENOUS DNA ADDUCTS S137
VINYL CHLORIDE
VC is a known human and animal carcinogen that induces
hepatic angiosarcomas (IARC, 1987). The carcinogenic
responses for VC are associated with relatively high exposures
( 50 ppm). To date, 197 VC workers have developed hepatic
angiosarcomas (Kielhorn et al., 2000). All these individuals
started work prior to the lowering of the occupational exposure
limit to 1 ppm in 1974. Early epidemiology studies also found
associations between VC exposure and brain tumors in workers
(Cooper, 1981; Waxweiler et al., 1976; Wong et al., 1991). As
the epidemiology studies got stronger through larger cohorts,
longer follow-up, and exposure was examined more thor-
oughly, this association disappeared (Ward et al., 2001). In
addition to occupational exposure and smoking, VC is present
in groundwater from many Superfund sites and some public
drinking water in parts per billion amounts as a result of
dechlorination of the common groundwater contaminants,
trichloroethylene, and perchloroethylene (ATSDR, 2006).
VC DNA Adducts and Mutagenicity
VC is a procarcinogen that requires metabolic activation,
with the primary enzyme involved being Cytochrome P450
2E1, which converts VC to chloroethylene oxide (CEO). CEO
covalently binds to DNA, inducing four DNA adducts (Fig. 4.).
The most prevalent DNA adduct is 7-(2-oxoethyl)guanine
(OEG), which represents ~98% of the adducts formed by VC.
OEG in not promutagenic, i.e., it does not cause mispairing
during DNA replication (Barbin et al., 1985). It is lost pri-
marily by chemical depurination, but some repair by glyco-
sylases is also possible. In either case, abasic sites represent
a repair intermediate. With daily exposure, OEG adducts
reach steady-state concentrations in ~7 days and have a T½ of
4 days (Mutlu, unpublished data). VC also induces three
exocyclic etheno DNA adducts 1,N6-ethenodeoxyadenosine
(edA), 3,N4-ethenodeoxycytosine (edC), and N2,3-ethenoguanine
(eG) (Bartsch et al., 1994; Guengerich and Persmark, 1994). eG
has been measured using gas chromatography/mass spectrometry
(GC/MS) and gas chromatography/high resolution mass spec-
trometry (GC/HRMS) following derivatization with or without
immunoaffinity enrichment (Fedtke et al., 1989, 1990a,b;
Morinello et al., 2001, 2002a,b). Most recently, eG was analyzed
following neutral thermal hydrolysis and HPLC enrichment with
LC-MS/MS pseudoSRM (Mutlu et al., 2010). Most research
analyzing edA and edC has utilized immunoaffinity-32P-
postlabeling (Nair et al., 1995; Reddy, 1993). Recently, an LC-
MS/MS method was applied using either immunoaffinity (Ham
et al., 2004) or HPLC (Gao, unpublished data) enrichment.
All three etheno adducts are promutagenic, as summarized in
Table 4. Mutations have been induced in site-specific
mutagenesis assays (Basu et al., 1993; Cheng et al., 1991;
Shibutani et al., 1996; Singer et al., 1991; Zhang et al., 1995)
as well as following in vitro exposure to CEO or chloroace-
taldehyde (Guengerich, 1992; Oesch and Doerjer, 1982).The
human K-ras gene is activated by a GC / AT base
substitution at the second base of codon 13. This mutation
was present in 5/6 human VC-induced angiosarcomas (Marion
et al., 1996) and is consistent with the known promutagenic
properties of eG and edC. Hollstein et al. (1994) reported AT
/ TA mutations in the p53 tumor suppressor gene in 2/4
human hepatic angiosarcomas analyzed in VC workers. These
mutations are consistent with the miscoding properties of edA.
Endogenous VC DNA Adducts
Etheno adducts have been identified in unexposed humans
and rats in several studies (Barbin et al., 2003; Bartsch et al.,
1994; Morinello et al., 2002a; Nair et al., 1995). In vitro
studies demonstrated that incubating nucleosides or
FIG. 4. Metabolism of VC and formation of DNA adducts from CEO.
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nucleobases with lipid peroxidation products resulted in the
formation of eA, eC, and eG (el Ghissassi et al., 1995; Ham
et al., 2000, 2004; Nair et al., 1996). Most recently,
endogenous OEG was also identified in [13C2]-VC–exposed
rats (Mutlu, unpublished data).
A review of human studies on DNA adducts associated
with inflammation and lipid peroxidation was published by
Nair et al. (2007). This paper includes data from many studies
on edA and edC, including nondiseased tissues. It reported
values ranging from not detected to 29 edA and edC adducts
per 109 parent bases. Median values of endogenous etheno
adducts present in a variety of tissues from 12 human autopsy
cases with no known exposure to VC ranged from 1.0 to
2.9 edA/108 dA and 1.9 to 4.8 edC/108 dC (Barbin et al.,
2003). The study by Barbin also examined aldehydic lesions
such as abasic sites and found 3.7–11.3 aldehydic DNA
lesions (ADL)/106 nt. Ethenoguanine has been less well
studied, with ~15 eG/108 G in both human liver and colon
(Hussain et al., 2000; Swenberg et al., 1999).
Several studies have examined DNA from unexposed
rodent tissues and demonstrated the presence of endogenous
etheno adducts. Using immunoaffinity/32P-postlabeling, con-
trol rat liver had ~0.4–5.8 edA/109 dA and 0.6–40 edC/109 dC
(Guichard et al., 1996; Nair et al., 2005). Guichard et al.
(1996) also reported ~2 edA/108 dA and 9 edC/108 dC in
lung and ~3 edA/108 dA and 10 edC/108 dC in kidney.
Ham et al. (2004) developed an LC-MS/MS assay for edA
and reported ~0.8 edA/108 dA in control and Aag null mouse
liver but 0.1 edC/108 dC in control mouse lung compared with
0.7 edC/108 dC in the lung tissues of Aag knockout mice.
Morinello et al. (2002b) utilized immunoaffinity GC-HRMS
to first show endogenous eG in rat liver and brain DNA. Liver
had ~4 eG/108 G, whereas brain had ~5.3 eG/108 G in control
animals. It is of interest that human tissues tended to have
greater amounts of endogenous etheno adducts than rodents.
Relationships of Exogenous/Endogenous VC DNA Adducts
Several studies have compared endogenous DNA adducts
identical to those induced by VC (Gao, unpublished data;
Mutlu et al., 2010). The most informative studies have utilized
1100 ppm [13C2]-VC exposures for 5 or 20 days (6 h/day) that
provided accurate information on both endogenous and
exogenous DNA adducts in the same DNA sample (Gao,
unpublished data; Morinello et al., 2002a,b; Mutlu et al.,
2010). Morinello et al. (2002b) examined adult rat liver and
brain DNA and demonstrated that 5.2 ± 1.2 endogenous eG/
108 G were present in hepatocyte DNA, whereas 55 ± 4.0
[13C2]-eG/10
8 G were formed following 5 days of exposure to
1100 ppm [13C2]-VC (6 h/day) and 110 ± 20 [
13C2]-eG/10
8 G
were formed following 20 days of exposure. In contrast, 5.4 ±
1.2 endogenous eG/108 G were present in brain, but no [13C2]-
eG was detectable following 5 or 20 days of exposure. This
strongly supports the more comprehensive epidemiology
studies that did not find a causal association between brain
tumors and VC exposure. We hypothesize that the chemical
instability of CEO formed in the liver does not allow it to be
transported to the brain where it can form DNA adducts,
whereas the endogenous adducts are formed from oxidative
stress arising within the brain.
Table 5 provides quantitative data for OEG, eG, and edA
from a study that also exposed rats to 1100 ppm [13C2]-VC for
5 days (6 h/day) (Gao, unpublished data; Mutlu, unpublished
data; Mutlu et al., 2010). Results similar to those of Morinello
et al. (2002b) were shown in adult liver DNA (4.1 ± 2.8
endogenous eG/108 G vs. 18.9 ± 4.9 [13C2]-eG/10
8 G). Using
sequential sacrifices 2, 4, and 8 weeks later, they demonstrated
that [13C2]-eG adducts had little or no repair, with a half-life of
150 days. In contrast, endogenous hepatic OEG was present at
TABLE 4
Miscoding Properties of VC DNA Adducts
7-(2-Oxoethyl)guanine (OEG) None
N2,3-Ethenoguanine (eG) G / A
3,N4-Ethenodeoxycytidine (edC) C / T
C / A
C / G
























Adult rats at end of exposure 0.2 ± 0.1 10.4 ± 2.3 4.1 ± 2.8 18.9 ± 4.9 4.9 ± 0.6 5.1 ± 0.6
2 Weeks postexposure 0.1 ± 0.03 0.4 ± 0.3 3.7 ± 3.1 14.2 ± 4.2 8.6 ± 0.9 n.d.
4 Weeks postexposure 0.2 ± 0.04 0.1 ± 0.06 3.1 ± 1.0 16.9 ± 1.6 6.2 ± 1.3 n.d.
8 Weeks postexposure 0.2 ± 0.07 n.d. 3.7 ± 1.5 13.2 ± 2.5 4.1 ± 0.5 n.d.
Note. n.d., not detected.
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2 ± 1 OEG/106 G at the end of the 5-day exposure and over the
next 8 weeks. [13C2]-OEG was present at the end of the 5-day
exposure at 104 ± 23 [13C2]-OEG/10
6 G, 4 ± 3 [13C2]-OEG/10
6
G 2 weeks later and was not detectable 4 or 8 weeks
postexposure. The half-life of [13C2]-OEG was calculated to be
4 days. In our laboratory, Gao developed a nano-UPLC-MS/
MS assay for edA to analyze same tissues (Gao, unpublished
data). She found 4.9 ± 0.6 endogenous edA/108 dA in the 1100
ppm [13C2]-VC–exposed rat liver compared with 5.1 ± 0.6
[13C2]-edA/10
8 dA. No [13C2]-edA adducts could be detected
in liver samples from rats killed 2, 4, or 8 weeks postexposure.
The study design did not allow accurate calculation of the half-
life of [13C2]-edA adducts, as the postexposure times were too
long. This is consistent with other data suggesting that edA is
rapidly repaired with a half-life of ~24 h (Ham et al., 2004).
These [13C2]-VC studies are the only data that discriminate
between endogenous and exogenous VC adducts, as all other
studies have been measuring a mixture of endogenous and
exogenous adducts. It is clear that markedly different half-lives
exist for edA, OEG, and eG.
Application of Data on Exogenous/Endogenous Adducts to
VC Risk
The hepatic angiosarcomas observed in workers exposed to
high workplace concentrations of VC provide compelling
evidence of its carcinogenicity in humans. A major question
remains nonetheless regarding the nature of the exposure-
response relationship: is it linear or not? Are these tumors
a high, sustained dose-only phenomenon, as has been observed
in the workplace, or might they also manifest at lower,
intermittent doses? Interestingly, the three promutagenic etheno
adducts of CEO that arise from VC metabolism exhibit
markedly different endogenous/exogenous ratios that can be
traced back to their markedly different half-lives, with the
etheno-G adduct having by far the longest half-life (in rats) of
150 days. Thus, continuous exposure for extended periods can
lead to higher exogenous/endogenous ratios for eG that would
translate into greater predicted relative risks using the bottom-
up approach. In contrast, OEG will reach steady-state levels in
7–10 days, and edA and edC will not increase over exposure
time. More research is needed to sort out the implications for
human cancer risk of short-lived, rapidly repaired adducts in
relation to long-lived, poorly repaired adducts.
ETHYLENE OXIDE
Ethylene oxide (EO) has been classified as a known human
carcinogen by IARC. This classification was based on limited
evidence in humans for LEU, breast, and stomach cancer,
sufficient evidence for carcinogenicity in experimental animals,
and an array of genetic toxicology data in humans and animals
(IARC, 1994). Ethylene oxide is a genotoxic chemical that
causes both chromosomal and gene mutations. To date, the
types of DNA damage responsible for creating EO mutations
remain unknown.
Ethylene Oxide DNA Adducts and Mutagenicity
Ethylene oxide is a direct-acting alkylating agent that binds
to DNA at several positions (Fig. 5). Numerous groups have
conducted research on the DNA and globin adducts of EO,
with most data collected during the last 20 years. The
advancement of analytical methods such as derivatization and
MS, HPLC with fluorescence detection, and the application of
32P-postlabeling of DNA adducts provided methods with
adequate sensitivity to accurately measure the DNA and globin
adducts of EO. Törnqvist et al. (1986) developed the Edman
degradation method for GC/MS analysis of N-terminal valine
adducts of EO in 1986. This method clearly demonstrated the
presence of hydroxyethylvaline adducts in unexposed humans
and animals. Subsequently, GC/MS and GC/HRMS methods
for detecting N7-(2-hydroxyethyl)guanine (7HEG), the major
DNA adduct formed by EO, were developed (Föst et al., 1989;
Wu et al., 1999), and 32P-postlabeling of DNA was used to
determine EO DNA adducts (Eide et al., 1999). More recently,
LC-MS/MS and HPLC coupled with accelerator MS have been
used to measure exogenous 7HEG (Marsden et al., 2007;
Rusyn et al., 2005). Whereas 7HEG makes up ~95% of the
DNA adducts, EO forms several additional minor DNA adducts
including N3-(2-hydroxyethyl)dA, N3-(2-hydroxyethyl)dU,
and O6-(2-hydroxyethyl)dG (La et al., 2010). 7HEG is not
considered a promutagenic DNA adduct but can depurinate
and produce an abasic site that could be mutagenic if present
during DNA replication. However, inhalation exposures of
rats to 100 ppm EO for 4 weeks (6 h/day, 5 days/week) did
not result in an increase in abasic sites (Rusyn et al., 2005).
When mice were exposed to ethylene or EO by inhalation for
4 weeks (6 h/day, 5 days/week) and HPRT mutant frequencies
were determined, there was no increase in mutations at 40,
1000, or 3000 ppm ethylene, which is equivalent to 4.5, 9, or
10 ppm EO. The lowest exposure that increased HPRT mutant
frequencies was 50 ppm EO (Swenberg et al., 2008). More
recently, EO mutagenicity was evaluated in the pSP189
shuttle vector being replicated in human Ad293 cells
(Tompkins et al., 2009). Even when plasmids containing
up to 29,000 7HEG adducts/108 nt were evaluated, no other
EO DNA adducts could be detected using sensitive LC-MS/
MS methods and no increases in mutations were found.
Only when very high exposures to EO were used and N1-
hydroxyethyldA (N1-HEdA), O6-hydroxyethyldG (O6-HEdG),
and N3-hydroxyethyldU (N3-HEdU) could be measured were
significant increases in mutations apparent. The half-lives of
these three adducts are much shorter than 7HEG because of
active DNA repair pathways. This plethora of data suggests that
EO is a relatively weak mutagen.
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Endogenous Ethylene Oxide DNA Adducts
Endogenous amounts of 7HEG in tissues from unexposed
rats and mice range from 1 to 4 7HEG/108 nt (Marsden et al.,
2007; Wu et al., 1999), whereas human liver had 58.5 ± 21.4
7HEG/108 nt and human lymphocytes had 48 ± 31 7HEG/108
nt (Wu et al., 1999). Thus, humans appear to have nearly 10-
fold higher amounts of endogenous 7HEG than are found in
rats and mice. Endogenous 7HEG arises from multiple
sources, including the generation of ethylene from methionine
oxidation, lipid peroxidation, and bacterial metabolism.
Endogenous ethylene is metabolized to EO in the liver,
circulates in the blood to expose all tissues, and is exhaled in
expired breath. Of considerable interest is the recent study by
Marsden (Marsden et al., 2009), who found that ip injections
of [14C2]-EO not only formed [
14C2]-labeled exogenous
7HEG but also caused dose-related increases in unlabeled,
endogenous 7HEG. They went on to demonstrate that the
increase in endogenous 7HEG was because of increased
oxidative stress. This may be the result of competition for
detoxication pathways between endogenous and injected
[14C2]-EO. Additional evidence for endogenous 7HEG was
provided by the demonstration of 7HEG in human urine
(Cushnir et al., 1993; Huang et al., 2008). The amounts of
7HEG in urine were lowest in nonsmokers with no
occupational exposure to EO.
Relationships of Exogenous/Endogenous Ethylene Oxide
DNA Adducts
Numerous studies have measured 7HEG in various tissues of
rats, mice, and humans exposed to EO. What must be clearly
understood is that such biomarker measurements actually
represent exposure to both endogenous and exogenous EO. To
some degree, the source can be ferreted out by comparing
exposed individuals to unexposed controls. However, the use
of stable isotope exposures, followed by adduct purification
and MS, is the only way to measure both endogenous and
exogenous 7HEG in DNA at the same time. To date, this has
not been reported for EO. As mentioned earlier, Marsden et al.
(2007, 2009) exposed mice to [14C2]-EO ip at doses of 0,
0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, or 0.1 mg/kg per day
for 3 consecutive days and harvested the tissues 4 h after the
last dose. The authors concluded that the responses in liver,
spleen, and stomach were dose dependent and not significantly
nonlinear. The authors also pointed out that several of the
lowest doses induced numbers of adducts that were below the
limit of quantitation for the AMS method (~20–50 7HEG/1012
nt). To put that in perspective with endogenous 7HEG, this
amount is 1000 times lower than endogenous 7HEG observed
in control rodent tissues and 10,000 times lower than measured
in normal human tissues. The molecular dose of 7HEG created
by such low exposures implies that only 1/1000 7HEG adducts
in a mouse and only 1/10,000 adducts in a human would arise
from exogenous exposure, assuming that rodents and humans
form equivalent molecular doses from equal exposures. The
endogenous EO adducts outnumber the exogenous adducts by
such a vast margin that the exogenous adducts are not likely to
be causal for EO-induced mutations or cancer. When looked at
from the perspective of the total number of endogenous DNA
adducts in a cell, it is clearly implausible.
Application of Data on Exogenous/Endogenous Adducts to
EO Risk
It is worth exploring implications of the bottom-up approach
that was taken herein for formaldehyde risk assessment in the
case of EO. Although the adduct data are more limited,
FIG. 5. Metabolism of ethylene and formation of DNA adducts from EO.
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potentially useful inferences can be drawn from what in-
formation is presently available. For example, it was noted
previously that the LOD for exogenous 7HEG adducts using
AMS (~20–50 adducts per 1012 nt) is approximately 1000-fold
lower than the measured endogenous amounts of these adducts
in human tissues. This implies, even for a simple linear model
of cancer risk, that the incremental risk above background
arising from exposures that produce fewer adducts than can be
currently detected must likewise be less than 1 in 1000.
Estimated relative risks (risk at a given exposure level divided
by the background risk) would thus be conservatively
constrained to be less than 0.001, a value far smaller than
could ever be detected in retrospective cohort mortality studies
of exposed workers. This ‘‘prediction’’ suggests that the limited
evidence in humans of increased LEU, breast, and stomach
cancer may in fact be false-positive findings. Of course, many
caveats apply to such extrapolations, and additional dose-
response data will be needed to support or refute the numerous
assumptions that are required to produce them.
CONCLUSIONS
Over the last 15 years, many researchers have investigated
relationships between DNA damage and repair, mutagenesis,
and carcinogenesis. This was also the era of discovery of an
ever-growing literature on endogenous DNA damage. During
this same period, risk assessment practices have gone from
minimal incorporation of mechanistic data and reliance on the
linearized multistage model for low-dose risk assessment to
strong emphasis on Mode of Action and the incorporation of
such scientific data into the risk assessment process. However,
this approach is not uniformly accepted, as some scientists and
risk assessors support the use of linear risk assessment with
little regard for the incorporation of science into the decision
making process, an approach outlined in Science and Decisions
(NRC, 2009). This paper highlights data for three chemicals
listed by IARC as known human carcinogens, which also form
DNA adducts identical to endogenous DNA damage. These
examples provide great insight into issues related to evalua-
tions of cancer causality and low-dose risk assessment.
The carcinogenicity of inhaled formaldehyde was discovered
30 years ago (Swenberg et al., 1980). Since that time, one of
the richest understandings of the key events involved in
carcinogenesis has come forth. Despite this, the recent draft
risk assessment of the U.S. EPA has ignored much of the
science and has proposed risks in tissues with no mechanistic
support that are magnitudes above what is plausible. The recent
paper of Lu et al., (2010a) was highlighted by this journal and
the editor wrote a special commentary (Lehman-McKeeman,
2010) that stated: ‘‘In their present work, Lu et al. have
provided the first definitive evaluation of DNA adducts arising
from endogenous and exogenous formaldehyde, a novel and
important contribution to the scientific literature. Moreover,
they have generated the type of data that should be given strong
consideration by toxicologists and risk assessors as the data and
their interpretations are used to improve the scientific basis of
human health risk assessment.’’ We have taken the challenge to
begin applying the type of data generated in Lu et al., (2010a)
and conducted additional research to better address comple-
mentary aspects of molecular dosimetry, species differences,
and DNA adduct persistence and the fact that formaldehyde is
an essential biochemical of every living cell. This information
was then utilized to generate a public health conservative
approach to risk assessment that made use of the new and
previously known biology and toxicology related to formalde-
hyde and cancer.
VC and EO also have clearly been shown to induce DNA
adducts identical to endogenous DNA adducts in experimental
animals and humans. Although less studied than formaldehyde,
the available information demonstrates that similar approaches
could be applied to these chemicals.
Going beyond chemicals that form identical endogenous
and exogenous DNA adducts, there are approximately 50,000
endogenous DNA lesions in every living cell. This steady-
state amount of DNA damage has long been considered to
represent a major source of cancer and other diseases. Despite
this, it has not been taken into consideration in risk
assessments in determining what exposures actually produce
disease. For that matter, epidemiology has not adequately
utilized information on biomarkers to assist in the de-
termination of causality. Such data can help support or refute
causal associations.
We propose that this approach is set in an embryonic state of
knowledge but strongly believe that public health and effective
regulation of chemicals will be strengthened by science-based
determinations of causality and promulgations of risk. To
achieve this, we must have better data on low-dose
mutagenicity, improved Mode of Action understanding that
covers high- to low-dose ranges, and species differences and
similarities. We can then move forward, embracing public
health protective actions that are based on science. This
includes the application of reasonable additional factors for
susceptible individuals.
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